oligonucleotides
First Patient Dosed in Ractigen Therapeutics' siRNA Drug Trial for SOD1-ALS
The drug, RAG-17, is a small interfering RNA therapeutic designed to target and knock down expression of the SOD1 protein.
The firm is changing its name and therapeutic focus ahead of a planned IND filing for its RNA-based OligoPhore therapy for KRAS-mutant CRC.